tranylcypromine has been researched along with Rhabdomyosarcoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Buettner, R; Hartmann, W; Kirfel, J; Merkelbach-Bruse, S; Riegel, R; Schildhaus, HU; Schüle, R; Sonobe, H; Steiner, S; Tanaka, S; Wardelmann, E | 1 |
| Bennani-Baiti, IM; Kovar, H; Llombart-Bosch, A; Machado, I | 1 |
2 other study(ies) available for tranylcypromine and Rhabdomyosarcoma
| Article | Year |
|---|---|
Lysine-specific demethylase 1 is highly expressed in solitary fibrous tumors, synovial sarcomas, rhabdomyosarcomas, desmoplastic small round cell tumors, and malignant peripheral nerve sheath tumors.
Topics: Biomarkers, Tumor; Cell Line, Tumor; Clorgyline; Desmoplastic Small Round Cell Tumor; Epigenesis, Genetic; Histone Demethylases; Humans; Monoamine Oxidase Inhibitors; Nerve Sheath Neoplasms; Rhabdomyosarcoma; Sarcoma, Synovial; Solitary Fibrous Tumors; Tranylcypromine | 2011 |
Lysine-specific demethylase 1 (LSD1/KDM1A/AOF2/BHC110) is expressed and is an epigenetic drug target in chondrosarcoma, Ewing's sarcoma, osteosarcoma, and rhabdomyosarcoma.
Topics: Bone Neoplasms; Cell Proliferation; Chondrosarcoma; Gene Expression Profiling; Histone Demethylases; Humans; Osteosarcoma; Rhabdomyosarcoma; Sarcoma, Ewing; Tranylcypromine | 2012 |